miR-146a mimic therapy protects against platelet-mediated thrombosis

Molecular Therapy 2026 Open access

Read full text
Authors: Sonia Águila, Juan C. García-Cañaveras, Laura Zapata-Martínez, Ana B. Arroyo, Nuria García‐Barberá, Salvador Carrillo‐Tornel, Pedro J. Guijarro-Carrillo, Paula González-Jiménez, Ana Latorre, Maria Luisa Lozano, Bernard Payrastre, José Rivera
+6 more Marie‐Pierre Gratacap, Raúl Méndez, Agustín Lahoz, Marcin Kortylewski, Rocío Gónzález‐Conejero, Constantino Martı́nez
DOI: 10.1016/j.ymthe.2026.07.019
Cited by: 1
References: 65

Abstract

mice prevented platelet aggregation in lungs by fully protecting them against thrombosis. In summary, our findings show that miR-146a deficiency leads to platelet hyperreactivity through metabolic reprogramming. Elevating miR-146a levels may be a therapy for preventing cardiovascular events.

Fields of Study & Subjects

Platelet Disorders and Treatments MicroRNA in disease regulation Antiplatelet Therapy and Cardiovascular Diseases

Publication details

Journal / source
Molecular Therapy
Publisher
Elsevier BV
Volume
34
Issue
9
Pages
5333–5351
Publication date
13 July 2026
Language
EN